{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:34:16Z","timestamp":1793237656700,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ymthe.2026.03.013","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:26:21Z","timestamp":1773246381000},"page":"3872-3884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1\/2 MARINA study"],"prefix":"10.1016","volume":"34","author":[{"given":"Tanya T.","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingying","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Delos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Malecova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jung","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur A.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam S.","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Michael","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1038-340X","authenticated-orcid":false,"given":"Yiming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.03.013_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000524734","article-title":"Global Prevalence of Myotonic Dystrophy: An Updated Systematic Review and Meta-Analysis","volume":"56","author":"Liao","year":"2022","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.ymthe.2026.03.013_bib2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1042\/BST0371281","article-title":"Pathogenic mechanisms of myotonic dystrophy","volume":"37","author":"Lee","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ymthe.2026.03.013_bib3","first-page":"385","article-title":"Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member","volume":"69","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.03.013_bib4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jmg.2008.058909","article-title":"The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients","volume":"45","author":"Botta","year":"2008","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymthe.2026.03.013_bib5","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1093\/hmg\/dds185","article-title":"Somatic instability of the expanded CTG triplet repeat in myotonic dystrophy type 1 is a heritable quantitative trait and modifier of disease severity","volume":"21","author":"Morales","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.03.013_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.gde.2017.01.007","article-title":"Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes","volume":"44","author":"Yum","year":"2017","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ymthe.2026.03.013_bib7","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/hmg\/ddl132","article-title":"Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy","volume":"15","author":"Lin","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.03.013_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1432-0436.2006.00060.x","article-title":"The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing","volume":"74","author":"Pascual","year":"2006","journal-title":"Differentiation"},{"key":"10.1016\/j.ymthe.2026.03.013_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006316","article-title":"Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy","volume":"12","author":"Wagner","year":"2016","journal-title":"Plos Genet."},{"key":"10.1016\/j.ymthe.2026.03.013_bib10","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/nar\/gkab022","article-title":"Targeted splice sequencing reveals RNA toxicity and therapeutic response in myotonic dystrophy","volume":"49","author":"Tanner","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.03.013_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1474-4422(23)00001-7","article-title":"Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1\/2a trial","volume":"22","author":"Thornton","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.03.013_bib12","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/hmg\/ddac254","article-title":"Dynamics and variability of transcriptomic dysregulation in congenital myotonic dystrophy during pediatric development","volume":"32","author":"Hale","year":"2023","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.03.013_bib13","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/acn3.52224","article-title":"RNA mis-splicing in children with congenital myotonic dystrophy is associated with physical function","volume":"11","author":"Hartman","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2026.03.013_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185426","article-title":"The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1","volume":"135","author":"Provenzano","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.03.013_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810491","article-title":"Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2","volume":"23","author":"Timchenko","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.03.013_bib16","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.drudis.2021.03.024","article-title":"Myotonic dystrophy type 1 drug development: A pipeline toward the market","volume":"26","author":"Pascual-Gilabert","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2026.03.013_bib17","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1212\/WNL.0000000000011002","article-title":"Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"96","author":"Heatwole","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2026.03.013_bib18","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/brain\/awy231","article-title":"Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial","volume":"141","author":"Bassez","year":"2018","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2026.03.013_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pediatrneurol.2020.08.001","article-title":"A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)","volume":"112","author":"Horrigan","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2026.03.013_bib20","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.03.013_bib21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJMoa2407326","article-title":"An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1","volume":"394","author":"Johnson","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.03.013_bib22","first-page":"487","article-title":"Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds","volume":"10","author":"Arandel","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymthe.2026.03.013_bib23","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/genes11111321","article-title":"Preliminary Findings on CTG Expansion Determination in Different Tissues from Patients with Myotonic Dystrophy Type 1","volume":"11","author":"Ballester-Lopez","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2026.03.013_bib24","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ana.23992","article-title":"Splicing biomarkers of disease severity in myotonic dystrophy","volume":"74","author":"Nakamori","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2026.03.013_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1097-2765(02)00563-4","article-title":"Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy","volume":"10","author":"Mankodi","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2026.03.013_bib26","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.celrep.2016.02.014","article-title":"Nfix Regulates Temporal Progression of Muscle Regeneration through Modulation of Myostatin Expression","volume":"14","author":"Rossi","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.03.013_bib27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.celrep.2013.12.025","article-title":"The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression","volume":"6","author":"Kalsotra","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.03.013_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.nbd.2014.05.026","article-title":"LDB3 splicing abnormalities are specific to skeletal muscles of patients with myotonic dystrophy type 1 and alter its PKC binding affinity","volume":"69","author":"Yamashita","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2026.03.013_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/gtc.12201","article-title":"ABLIM1 splicing is abnormal in skeletal muscle of patients with DM1 and regulated by MBNL, CELF and PTBP1","volume":"20","author":"Ohsawa","year":"2015","journal-title":"Genes Cells."},{"key":"10.1016\/j.ymthe.2026.03.013_bib30","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1038\/s41598-018-24156-x","article-title":"Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy","volume":"8","author":"Wojciechowska","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.03.013_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.03.013_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.03.013_bib33","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.03.013_bib34","doi-asserted-by":"crossref","first-page":"E5593","DOI":"10.1073\/pnas.1419161111","article-title":"rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data","volume":"111","author":"Shen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.03.013_bib35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.ymthe.2026.03.013_bib36","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2026.03.013_bib37","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1073\/pnas.94.14.7394","article-title":"Transcriptional abnormality in myotonic dystrophy affects DMPK but not neighboring genes","volume":"94","author":"Hamshere","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.03.013_bib38","doi-asserted-by":"crossref","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr. Protoc. Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.03.013_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/ptj\/74.3.253","article-title":"Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group","volume":"74","author":"Personius","year":"1994","journal-title":"Phys. Ther."},{"key":"10.1016\/j.ymthe.2026.03.013_bib40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2044-5040-1-34","article-title":"Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders","volume":"1","author":"Mamchaoui","year":"2011","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ymthe.2026.03.013_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.celrep.2013.12.013","article-title":"RNAi factors are present and active in human cell nuclei","volume":"6","author":"Gagnon","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.03.013_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.ymthe.2026.03.013_bib43","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/2472555218761102","article-title":"MyoScreen, a High-Throughput Phenotypic Screening Platform Enabling Muscle Drug Discovery","volume":"23","author":"Young","year":"2018","journal-title":"SLAS Discov."},{"key":"10.1016\/j.ymthe.2026.03.013_bib44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.isci.2018.12.019","article-title":"Pluripotent Stem Cell-Based Drug Screening Reveals Cardiac Glycosides as Modulators of Myotonic Dystrophy Type 1","volume":"11","author":"Maury","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2026.03.013_bib45","series-title":"Guide for the Care and Use of Laboraory Animals","author":"Council","year":"2011"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600198X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600198X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:22:37Z","timestamp":1793236957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162600198X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S152500162600198X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.013","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1\/2 MARINA study","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}